ProCE Banner Activity

IMEA 055 FAST: BIC/FTC/TAF for Rapid Initiation of ART in Test-and-Treat Model

Slideset Download
Conference Coverage
In this small test-and-treat study, regimen was more than 80% effective at suppressing HIV-1 RNA at Week 24 with no treatment-emergent resistance seen in patients who did not achieve viral suppression; very low incidence of grade 3/4 or serious adverse events was seen.

Released: November 02, 2021

Expiration: November 01, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

ViiV Healthcare